Larimar Therapeutics Files 8-K

Ticker: LRMR · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1374690

Larimar Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLarimar Therapeutics, Inc. (LRMR)
Form Type8-K
Filed DateJan 10, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, sec-filing

Related Tickers: LRMR

TL;DR

Larimar Therapeutics (LRMR) filed an 8-K, confirming HQ and stock listing.

AI Summary

On January 10, 2025, Larimar Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at Three Bala Plaza East, Bala Cynwyd, Pennsylvania, 19004. Larimar Therapeutics, Inc. is registered in Delaware and its common stock trades on the Nasdaq Global Market under the ticker symbol LRMR.

Why It Matters

This 8-K filing provides updated corporate information and confirms the company's reporting status with the SEC.

Risk Assessment

Risk Level: low — This is a routine corporate filing with no new material financial or operational information disclosed.

Key Players & Entities

  • Larimar Therapeutics, Inc. (company) — Registrant
  • January 10, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 001-36510 (other) — Commission File Number
  • 20-3857670 (other) — IRS Employer Identification No.
  • Three Bala Plaza East, Bala Cynwyd, Pennsylvania, 19004 (address) — Address of Principal Executive Offices
  • LRMR (ticker) — Trading Symbol for Common Stock
  • Nasdaq Global Market (exchange) — Name of exchange where Common Stock is registered

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is a current report filed by Larimar Therapeutics, Inc. to disclose information as of January 10, 2025, including its principal executive offices and stock exchange listing.

When was the earliest event reported in this filing?

The earliest event reported in this filing is dated January 10, 2025.

Where are Larimar Therapeutics, Inc.'s principal executive offices located?

Larimar Therapeutics, Inc.'s principal executive offices are located at Three Bala Plaza East, Bala Cynwyd, Pennsylvania, 19004.

On which stock exchange is Larimar Therapeutics, Inc.'s common stock traded?

Larimar Therapeutics, Inc.'s common stock is traded on the Nasdaq Global Market.

What is the trading symbol for Larimar Therapeutics, Inc.'s common stock?

The trading symbol for Larimar Therapeutics, Inc.'s common stock is LRMR.

Filing Stats: 464 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-10 07:22:06

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market

Filing Documents

01 Other Events

Item 8.01 Other Events. On January 10, 2025, Larimar Therapeutics, Inc. (the " Company ") posted on its website an updated slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Larimar Therapeutics, Inc. Corporate Presentation, dated January 10, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: January 10, 2025 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.